Laboratory testing for cytomegalovirus among pregnant women in the United States: a retrospective study using administrative claims data

Table 4 Rates of routinely recommended laboratory tests for pregnant women ^a , and rates of CMV-specific testing among pregnant women ^a with claims for routinely recommended laboratory tests, MarketScan, 2009

Routinely recommended laboratory tests for pregnant women^a	Pregnant women^a	Pregnant women^awith CMV-specific testing^b
	# (%)	# (%)
Anemia testing	10,033 (13)	146 (1.5)
Glucose testing	54,989 (71)	1,228 (2.2)
Urine testing	54,947 (71)	1,311 (2.4)
Syphilis testing	65,047 (84)	1,613 (2.5)
Chlamydia testing	49,730 (64)	1,225 (2.5)
HIV testing	57,262 (74)	1,530 (2.7)
Hepatitis B testing	23,011 (30)	800 (3.5)
Rubella testing	15,546 (20)	650 (4.2)

Note: CMV, cytomegalovirus; PCR, polymerase chain reaction; IgG, Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing; EIA, enzyme immunoassay.
^aPregnant women defined as female enrollees who were 1) aged 15–44 years, 2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in Appendix) between October-December 2009.
^bCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and CMV PCR testing.

ISSN: 1471-2334